Compare OMDA & CGEM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OMDA | CGEM |
|---|---|---|
| Founded | 2011 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Nursing Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 999.4M |
| IPO Year | 2025 | 2020 |
| Metric | OMDA | CGEM |
|---|---|---|
| Price | $14.44 | $10.23 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 12 | 12 |
| Target Price | $26.92 | ★ $34.70 |
| AVG Volume (30 Days) | ★ 1.2M | 799.9K |
| Earning Date | 11-05-2026 | 11-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 94.27 | N/A |
| EPS | ★ 0.14 | N/A |
| Revenue | ★ $260,210,000.00 | N/A |
| Revenue This Year | $30.17 | N/A |
| Revenue Next Year | $20.40 | N/A |
| P/E Ratio | $104.93 | ★ N/A |
| Revenue Growth | ★ 53.24 | N/A |
| 52 Week Low | $10.28 | $8.23 |
| 52 Week High | $25.45 | $23.19 |
| Indicator | OMDA | CGEM |
|---|---|---|
| Relative Strength Index (RSI) | 29.92 | 30.81 |
| Support Level | $14.01 | N/A |
| Resistance Level | $15.11 | $16.31 |
| Average True Range (ATR) | 0.92 | 1.25 |
| MACD | -0.38 | -0.28 |
| Stochastic Oscillator | 4.98 | 7.50 |
Omada Health Inc empowers individuals to make lasting health changes through personalized, virtual care between doctor's visits. The integrated platform of the company supports members with cardiometabolic conditions like prediabetes, diabetes, hypertension, musculoskeletal issues, and behavioral health needs. The company's specialized care tracks also assist members using GLP-1 medications. The company delivers measurable health outcomes and value for employers, health plans, health systems, and pharmacy benefit managers.
Cullinan Therapeutics Inc is a clinical-stage biopharmaceutical company developing therapies for autoimmune diseases and cancer. Its development pipeline comprises the following drug candidates: CLN-978, a CD19xCD3 bispecific T cell engager that is being developed for autoimmune diseases; CLN-049, a FLT3xCD3 bispecific T cell engager being evaluated in an ongoing clinical trial in patients with relapsed/refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS); Velinotamig, a BCMAxCD3 bispecific T cell engager being developed to counter autoimmune diseases; and Zipalertinib, being developed as a treatment for non-small cell lung cancer. Additionally, the company is developing several preclinical programs in autoimmune diseases and oncology.